Advertisement

Topics

Crohn's & Colitis Foundation of America Company Profile

22:20 EDT 22nd March 2019 | BioPortfolio

The Crohn's & Colitis Foundation of America is the largest non-profit, volunteer-driven organization dedicated to finding a cure for Crohn's disease and ulcerative colitis, and it ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with approximately 79 cents of every dollar the Foundation spends going to mission-critical programs. The organization is committed to improving the quality of life of children and adults with inflammatory bowel disease (IBD) through research, education and support services, offering resources like the Information Resource Center (IRC), which serves as the central source for information and guidance for IBD patients. Information Resource Center specialists respond to an average of 13,000 inquiries and requests annually, and over 30,000 brochures and fact sheets are mailed to patients and caregivers through the IRC every year. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information visit www.ccfa.org or call the Foundation at 888.MY.GUT.PAIN to find a local chapter, and/or disease-specific education, support and treatment information.


News Articles [995 Associated News Articles listed on BioPortfolio]

Reporters invited to attend leading IBD meeting: Crohn's & Colitis Congress®

(American Gastroenterological Association) The Crohn's & Colitis Congress, the premier conference for inflammatory bowel diseases (IBD) health care providers and researchers, invites media to register...

Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation

BEVERLY, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is...

Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference

BEVERLY, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide this update on Bril...

Predictimmune and the Crohn’s & Colitis Foundation Announce a Joint Study to Validate and Prove Efficacy of First Prognostic Test for IBD in the US Market

The jointly-sponsored study is expected to advance progress towards personalised medicine for IBD patients in the US PredictImmune, developers of pioneering prognostic tools f...

New Real-World Data Analyses Support the Long-Term Use of Entyvio in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn’s Disease

Deerfield, IL, October 8, 2018 – Takeda Pharmaceuticals U.S.A., Inc., (“Takeda”) today announced the presentation of new long-term efficacy real-world data analyses for Entyvio® (vedolizumab)...

Families Caring for Individuals with Crohn's Disease and Ulcerative Colitis to be Focus of Caregiving Study

The National Alliance for Caregiving, Crohn’s and Colitis Foundation, and ImproveCareNow Partner to Understand the Impact of Inflammatory Bowel Diseases (IBD) on Caregivers WASHINGTON (PRWEB) Septem...

Crohn's, Colitis May Be Tied to Prostate Cancer

FRIDAY, Dec. 14, 2018 -- Men with inflammatory bowel disease have a significantly greater risk of prostate cancer, a new study finds. About 1 million men in the United States have inflammatory bowel d...

Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation

SYDNEY, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...

Drugs and Medications [289 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [america's healthcare at home, inc. ]

Oxygen

Oxygen [air liquide america l.p.]

NA

Nitrogen [linde gas north america llc]

NITROGEN, COMPRESSED

Entyvio [takeda pharmaceuticals america, inc.]

These highlights do not include all the information needed to use ENTYVIO safely and effectively. See full prescribing information for ENTYVIO.ENTYVIO (vedolizumab) for injection, for intravenous use...

Humira [a-s medication solutions]

These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA (adalimumab) injection, for subcutaneous useInitial...

PubMed Articles [1243 Associated PubMed Articles listed on BioPortfolio]

Diffuse colitis cystica profunda in Crohn's disease: A potential diagnostic pitfall.

Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome.

We aim to identify the differences in colonic mucosal transcriptome between Crohn's disease (CD) and ulcerative colitis (UC) for a better understanding of the molecular pathology.

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Early treatment of Crohn's disease (CD) is required to optimize patient outcomes. To this end, we need to gain a better understanding of the molecular changes at the onset of CD.

Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn's Disease and Ulcerative Colitis.

Innate lymphoid cells [ILC] have been suggested to play a role in inflammatory bowel disease [IBD]. Here, we investigated the ILC compartment in intestinal biopsies and blood from distinct patient gro...

Post-operative entero-cutaneous fistula closure by Over-The-Scope clip in Crohn's disease.

Clinical Trials [1645 Associated Clinical Trials listed on BioPortfolio]

Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis

Although Crohn's disease and ulcerative colitis are the main subtypes of inflammatory bowel disease, they differ substantially in disease behavior, prognosis, and treatment paradigm. Howev...

Risk Factors for Microscopic Colitis

Microscopic colitis is a common cause of watery diarrhea, particularly in the elderly. Although the incidence is comparable to ulcerative colitis and Crohn's disease, the etiology is unkno...

A Phase 2, Randomized, Double-Blind, Dose-Ranging Study With Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active ulcerative colitis or Crohn...

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of u...

Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

The purpose of this study is to monitor ongoing safety in subjects with ulcerative colitis (UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying subjects who, i...

Companies [2367 Associated Companies listed on BioPortfolio]

RMEI Medical Education (RMEI) and Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation (the Foundation) is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The F...

The Crohn's & Colitis Foundation of America

Crohns & Colitis Foundation of America

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 100,000 pediatric patients. The cause of Crohn's diseas...

Crohn's & Colitis Foundation of America

The Crohn's & Colitis Foundation of America is the largest non-profit, volunteer-driven organization dedicated to finding a cure for Crohn's disease and ulcerative colitis, and it ranks third among le...

Crohn'sAdvocate Program

Developed as a support and advocacy program for the half a million Americans affected by Crohn's disease, the Crohn'sAdvocate(TM) program was launched nearly a year ago by UCB. The program takes a 36...

More Information about "Crohn's & Colitis Foundation of America" on BioPortfolio

We have published hundreds of Crohn's & Colitis Foundation of America news stories on BioPortfolio along with dozens of Crohn's & Colitis Foundation of America Clinical Trials and PubMed Articles about Crohn's & Colitis Foundation of America for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Crohn's & Colitis Foundation of America Companies in our database. You can also find out about relevant Crohn's & Colitis Foundation of America Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...


Corporate Database Quicklinks



Searches Linking to this Company Record